The top ten best-selling anti-cancer drugs in 2018, the global sales of anti-cancer drugs are expected to reach 200 billion U.S. dollars in 2022

In 1997, paclitaxel, the anticancer drug, became the first "heavyweight player" with sales of more than $1 billion Twenty years later, according to a report released last year by iqvia's Institute of human data science, the annual average cost of a new cancer drug launched in 2017 was more than $150000, compared with $79000 in 2013 Iqvia pointed out in the report of global oncology drug trends 2018 that since 2012, the expenditure on cancer treatment in the United States has doubled, reaching nearly $50 billion in 2017, while the total cost of cancer drugs in the rest of the world is $60 billion Two thirds of the growth in cancer drug sales in the United States is due to treatment programs launched in the past five years, with 14 new cancer therapies launched in 2017 alone What's more, iqvia predicts that by 2022, at an annual growth rate of 12% - 15%, the sales volume of cancer drugs in the United States will double again, reaching $100 billion, and the sales volume outside the United States will be the same In this way, the global cancer drug market sales will reach 200 billion US dollars in three years On April 16, ajmc, together with its Institute for value based medicine, held a symposium entitled "improving the quality of cancer treatment in the changing value-based medical landscape" in whiteplains, New York Participants raised the challenges of controlling the cost of cancer drugs "It's unrealistic to spend $18000 a month on drugs," said Manuel C Perry, head of cancer treatment models at Crystal run health In order to achieve free drug use for patients, we and other clinics must overcome the obstacles of drug reimbursement; drug welfare management agencies and pharmaceutical companies need better response measures; if the government fails to negotiate with pharmaceutical companies, it should take some other cost control strategies In order to change the status quo, we must consider the cost control, the value orientation and the possible consequences in the future " Gen (Genetic Engineering & Biotechnology News) lists the top ten best-selling prescription drugs based on the sales or net sales in 2018 announced by bio / pharmaceutical companies in news bulletins, annual reports, investor materials and teleconferences In the list of 15 best-selling drugs in 2018 listed in the front row of gen, more than half of the anti-cancer drugs have entered the top 10 best-selling anti-cancer prescription drugs list, and the third drug Revlimid in the list corresponds to the top of the list Ranking 11-15 in the list and corresponding drugs are: Velcade (bortezomii) Co developed by Takeda pharmaceutical and Johnson & Johnson, jakafi (or jakavi) Co developed by inset and Novartis, perjeta (patozumab) developed by Genentech, Gardasil / Gardasil developed by MSD 9 (Gardasil, a cervical cancer vaccine) and zytiga (abitrone acetate) developed by Johnson & Johnson Last year, sales of these drugs ranged from $2274 million to $3498 million Here are the details of the top ten best-selling anti-cancer prescription drugs by name, R & D provider, drug type, sales in 2018 and 2017, and percentage change between two years The total sales volume of anticancer drugs in 2018 was US $63.58 billion, up 17.5% from US $54.126 billion in 2017 Six of the seven companies with sales growth achieved double-digit growth Revlimid was developed by sair gene company Type of drug: Thalidomide analog Sales in 2018: 9.685 billion Sales in 2017: 8.187 billion Percentage change: 18.3% 2opdivo was developed by BMS and Ono Type of drug: programmed death receptor-1 (PD-1) antibody Sales in 2018: $7.57 billion (BMS: $6.735 billion, Ono: $835 million) sales in 2017: $5.763 billion (BMS: $4.948 billion, Ono: $815 million) change percentage: 31.4% 3keytruda drug type developed by MSD: programmed death receptor-1 (PD-1) antibody sales in 2018: $7.171 billion 2017 sales: USD 3.809 billion change percentage: 88.3% 4 Herceptin drug type developed by Genentech: HER2 / neu receptor antagonists 2018 sales: USD 6.951 billion 2017 sales: USD 6.983 billion change percentage: - 0.5% 5 Avastin drug type developed by Roche: VEGF antibody Sales in 2018: $6.822 billion sales in 2017: $6.662 billion change percentage: 2.4% 6 rituxan / mabthera (rituximab) drug type developed by Genentech and Biogen Idec: anti-CD20 antibody sales in 2018: $6.75 billion sales in 2017: $7.298 billion change percentage: - 7.5% (the sales volume does not include Biogen's part, because the company only disclosed the sum of pretax profits of rituxan and albantozumab gazyva, and did not list rituxan separately Biogen reported pre tax profits of $1432 million for both drugs in 2018 and $1316 million in 2017.) 7 Imbruvica (irutini) and J & J cooperate to develop drug type: kinase inhibitor sales in 2018: 6.205 billion US dollars (abbvie: 3.59billion US dollars, J & J: 2.615 billion US dollars) sales in 2017: 4.466 billion US dollars (abbvie: 2.573 billion US dollars, J & J: 1.893 billion US dollars) change percentage: 38.9% 8neulasta / peglasta (ethylene glycol non-gristin) is jointly developed by Amgen and Kyowa Hakko Kirin Type of drugs: white cell growth factor sales in 2018: 4.684 billion (Amgen: 4.475 billion, Kyowa Hakko Kirin: 209 million) 2017: 4.716 billion (Amgen: 4.534 billion, Kyowa Hakko Kirin: $182 million) change percentage: - 0.7% 9ibrance (pabosini) developed by Pfizer drug type: kinase inhibitor sales in 2018: $4118 million sales in 2017: $3126 million change percentage: 16.3% (Pfizer said that although sales were up from the same period last year, the one-time price adjustment for sales in 2017 had a negative impact on international sales of ibrance, which was related to the final settlement agreement in some European developed country markets.) 10xtandi is jointly developed by Asteris pharma and Pfizer The type of drug: androgen receptor inhibitor sales in 2018: $3.624 billion (Asteris: $2.925 billion, Pfizer: $699 million) sales in 2017: $3.116 billion (Asteris: $2.526 billion, Pfizer: $509 million) Percentage change: 16.3% reference link: https:// source: arterial network Author: mailman